Real World Evidence and the Evolving Cancer Center
Jack London, PhDResearch Professor Emeritus of Cancer Biology
Thomas Jefferson UniversityPhiladelphia, Pennsylvania USA
2
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
REAL WORLD EVIDENCE (RWE)
Real world evidence (RWE) in medicine means evidence
obtained from real world data (RWD), which are
observational data obtained outside the context of
randomized controlled trials (RCTs) and generated during
routine clinical practice.Definition from Wikipedia
3
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
CANCER CENTER DATA
• Basic science results
• Clinical research trial results
• Data generated from patient clinical practice
RWDanalysis
RWE
4
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
RWD à RWE
Two considerations affect the value of RWE:
1. The quality of the RWD
2. The accuracy of the analysis that creates RWE from RWD
5
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
REAL WORLD DATA
RWD is generated by extracting data which is stored in electronic health records (EHR), billing activities databases, registries, patient-generated data, and now perhaps, mobile devices.
These data are not generated for research, but rather for patient management and billing uses.
The use of these data for research is secondary.
6
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
PATIENT DATA SOURCES FOR SECONDARY USE IN RESEARCH
o Hospital Electronic Medical Record (EMR)o Departmental information systems
• Pathology (Laboratory and Anatomic Pathology)• Radiology• Radiation Oncology systems
o Registries• Cancer registries (often government mandated)• Study registries (clinical investigator-driven)• Clinical trials management systemso Biobank management systems
o Clinical text reportso pathology reportso physician noteso discharge summaries
7
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
HOSPITAL ELECTRONIC MEDICAL RECORD
o Typically available patient data includeso demographicso diagnoseso procedureso medicationso laboratory resultso clinical reports
o Advantageso comprehensive, continually updated, patient clinical data set
oDisadvantageso often has “dirty” datao some data locked in text reports, requiring natural language processing extractiono lack of needed granularity (particularly true of cancer diagnostic data)
8
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
TYPICAL EMR CANCER DIAGNOSES (ICD9 / ICD10)
Malignant neoplasm of the colon (ICD9 153.9, ICD10 C18.9)Malignant neoplasm of the breast (ICD9 174.9, ICD10 C50.9)
Malignant neoplasm of the lung (ICD9 162.9, ICD10 C34.9)
No indication of tumor histology, behavior or disease stage
such as, localized adenocarcinoma of the colon, with no evidence of distant metastasis (i.e., stage I, II, or III)
primary site – histology (behavior) – stage
Therefore EMR data not granular enough for cancer research
9
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
PATHOLOGY SYNOPTIC REPORTS
However, when available from the EMR, College of American Pathologists
(CAP) synoptic reports – comprehensive pathology reporting of a cancer
specimen – can provide detailed cancer diagnostic data, specific to the
particular cancer.
10
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
CANCER (TUMOR) REGISTRY
o Typically includes comprehensive data set for cancer patients, spanning all clinical
oncology departments
o tumor histology and behavior
o disease stage
o recurrence
o treatment
o disease-specific factors
§ ER, PR, HER2 status for breast
§ Gleason score for prostate
o Advantages
o Human curated (trained abstractors) à accurate data
o Regional data model standards exist (NAACCR in U.S.)
o Disadvantages
o Because of human curation the data entry can lag by 4 to 6 months, or even longer.
o In the U.S., only follows patients initially diagnosed at that institution thereby ignoring patients initially
seen elsewhere but being treated locally.
11
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
CLINICAL TEXT REPORTS
Important clinical information (e.g., cancer stage, patient response
to treatment) is often found only in text reports (e.g., pathology,
physician notes).
These data must be extracted using Natural Language
Processing.
12
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
ANALYSIS OF RWD à RWE
Proper analysis of RWD is required to produce useful RWE.
Just as with basic science or clinical trial research, analyses of
RWD have to eliminate confounding factors that would lead to
spurious conclusions.
13
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
21ST CENTURY CURES ACT – EXPANDS THE ROLE OF RWE
The 21st Century Cures Act (the “Cures Act”) requires the FDA to develop a framework and guidance for evaluating RWE
• in the context of drug regulation to support approvals of new indications for previously approved drugs,
• and to support or fulfill post-approval study requirements.
Definition from Wikipedia.
14
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
TO BE DISCUSSED …
RESEARCH DATA ANALYTICS AT JEFFERSON
15
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
JEFFERSON RESEARCH DATA ANALYTICS TIMELINE
2010 2011 2012 2013 2014 2015 2016 2017
i2b2 pilot project
Deployment of i2b2 research
data mart (RDM).
Expansion of RDM to include specimen and tumor registry ontologies and
data
Developed methodology
for the prediction of clinical trial
accrual using the RDM
Addition of i2b2 “omic” data
ontology and data
TriNetX project starts
TriNetX deployment
includes tumor
registry data.
TriNetX deployment
includes genomics
data.TriNetX
collaborative network with
UTSW
TriNetX NLP project
starts.TJU
migrates to Epic EMR.
16
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
SKCC’S RESEARCH DATA MART DEPLOYMENT
Today, more than 180 million observations on over 3 million patients, refreshed weekly
• EMR patient data (demographics, diagnoses, medications, labs and procedures)
• Cancer registry data (tumor histology, stage, recurrence, treatment and disease-specific factors)
• “Omic” molecular diagnostic patient data o both in-house Jefferson NGS lab and outsourced Foundation Medicine resultso Currently > 400 genes with > 15,000 mutations
• Biospecimen annotation from biobanking systemo Specimen anatomic origin, class, type, pathology and slide images
17
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
HYPOTHESIS GENERATIONCOHORT IDENTIFICATION
• USE CASE: A clinical researcher wants to assess the feasibility of finding sufficient non-small cell lung cancer patients expressing ROS1 mutations for a clinical trial
RESEARCH DATA ANALYTICS USE OF RWD
• USE CASE: A neuroscientist wishes to access patient data to explore possible links between PSEN2 mutations and early onset Alzheimer's disease
18
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
USING RWD FOR CLINICAL TRIAL DESIGN
Use TriNetX platform to determine anticipated Jefferson cohort size for a proposed clinical trial.
Consider a trial for patients with locally advanced colon cancer with mutation(s) in KRAS and/or BRAF and/or PIK3CA gene(s) [NCT01108107]
• Inclusion criteriao stage 2 or 3 colon cancero KRAS, BRAF, and/or PIK3CA mutation testing determined in a CLIA-certified lab
• Exclusion criteriao Clinically significant cardiovascular disease (including myocardial infarction, unstable angina,
symptomatic congestive heart failure)
19
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
QUERY BASED ON TRIAL ELIGIBILITY CRITERIA
20
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
COHORT RWD DEMOGRAPHICS
21
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
COHORT RWD MOLECULAR DIAGNOSTICS
22
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
COHORT RWD PREDICTED ACCRUAL
23
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
USE RWD/RWE FOR HYPOTHESIS GENERATION
With RWD available over the TriNetX Research Network,
compare survival of lung cancer patients treated with
OPDIVO (nivolumab) vs KEYTRUDA (pembrolizumab)
24
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
RWD TO RWE VIA THE TRINETX RESEARCH NETWORK
Form cohorts of lung cancer patients treated with OPDIVO (nivolumab) or KEYTRUDA (pembrolizumab)
25
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.
ANALYSES OF THE TWO COHORTS
Patients treated with KEYTRUDA show better survival than those treated with OPDIVO
26
Copyright © 2017 Thomas Jefferson University. All Rights Reserved. Confidential.